Open-Label Extension of Other SZ1839 (Iressa) Trials

A trial to assess patients who have been treated with Iressa in a previous clinical trial and may benefit from continued treatment with Iressa.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Received treatment in a previous Iressa clinical trial
Provided Informed Consent to participate in the trial
30 days or less since completing the previous Iressa trial.

Exclusion criteria

Radiotherapy completed more than 14 days before starting treatment in this trial
Incomplete healing from prior surgery
Withdrawal from previous Iressa trial due to unacceptable toxicity to major organs

Treatment and study plan

gefitinib (Iressa)

Drug

Iressa

Primary outcomes

Adverse Events

Time frame: Every 28 days

Secondary outcomes

Progression Free Survival

Time frame: Every 28 days
Survival

Time frame: Every 28 days

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Multi-Centre, Open-Label Extension Trial of Treatment With ZD1839 (Iressa) in Patients Who Have Been Treated in Other ZD1839 Clinical Trials and May Benefit From Continued Monotherapy ZD 1839.

Important dates

Study start: 2000
Study completion: 2003
First posted: Mar 14, 2008
Registry last updated: Apr 22, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed